ASCO: Combo Regimen Effective in CLL With Coexisting Conditions
TUESDAY, June 4, 2019 -- Venetoclax-obinutuzumab is associated with longer progression-free survival than chlorambucil-obinutuzumab among patients with untreated chronic lymphocytic leukemia (CLL) and coexisting conditions, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2019 Category: Pharmaceuticals Source Type: news
Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Roche today announced results from the pivotal phase III CLL14 study in previously untreated chronic lymphocytic leukaemia (CLL) showing that Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - June 4, 2019 Category: Pharmaceuticals Source Type: news
Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Roche today announced results from the pivotal phase III CLL14 study in previously untreated chronic lymphocytic leukaemia (CLL) showing that Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - June 4, 2019 Category: Pharmaceuticals Source Type: news
IMBRUVICA ® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 3, 2019 Category: Pharmaceuticals Source Type: news
Ibrutinib, Venetoclax Active in High - Risk, Seniors With CLL
Findings seen in phase 2 study of combo regimen for first - line treatment of chronic lymphocytic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 30, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news
